Superworth

Eledon Pharmaceuticals price to book ratio ELDN

Market value divided by the book value of the company's net assets, since 2014.

Today, Oct 23, 2026
5.7×
10-year median
0.9×
Against its 10-year history
95th
percentile: 0 is its lowest day, 100 its highest
10-year range
0.2× to 8.7×
Peer median
1.6×

Eledon Pharmaceuticals' price to book ratio is 5.7× as of Oct 23, 2026.

That is above its ten-year median of 0.9×, higher than on 95% of days in the last ten years.

Over that time it ranged from 0.2× in Mar 2023 to 8.7× in Aug 2026.

The median for 10 large drugmakers of a similar size is 1.6×.

Price to book ratio over time

The dashed line is the 10-year median and the shaded band the middle half of its days.

Open the interactive chart, with overlays and comparisons

Year by year

YearEnd of yearLowHigh
2026 so far5.7×2.6×8.7×
20252.7×1.4×5.1×
20243.4×0.4×3.7×
20230.5×0.2×0.7×
20220.2×0.2×0.4×
20210.4×0.3×1.2×
20201.0×0.3×3.0×
20190.6×0.4×2.8×
20180.9×0.9×3.0×
20171.4×0.4×1.5×
20160.7×0.6×3.2×
20152.7×2.2×3.8×
20143.2×3.1×3.4×

Against its peers

Companies in Drug Manufacturers - General nearest Eledon Pharmaceuticals' size, closest first, today.

CompanyPrice to book ratio
ELDNEledon Pharmaceuticals5.7×
NATRNatures Sunshine Products1.3×
LFVNLifevantage2.2×
ARVNArvinas0.8×
SPROSpero Therapeutics1.5×
PBYIPuma Biotechnology4.1×
IRWDIronwood Pharmaceuticalsn/m
ZVRAZevra Therapeutics2.7×
CRMDCorMedix1.3×
ATNMActinium Pharmaceuticals1.6×
COLLCollegium Pharmaceutical2.4×
Peer median1.6×

What the price to book ratio tells you

Market value divided by the accounting value of the company's net assets. Below 1 means the market values the business at less than what it owns on paper.

Book value misses brands, software and people, so asset-light companies always look expensive on it. Most useful for banks and industrials.

More on Eledon Pharmaceuticals

Valuation data, not investment advice. Prices as of . Reported figures come from the company's filings with the SEC.